CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

PURPOSE: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Lancet, Jeffrey E., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C., Medeiros, Bruno C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
RAPID COMMUNICATION
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127025/
https://ncbi.nlm.nih.gov/pubmed/30024784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.6112
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados